Generic Drugs: World Market 2013-2023

  • November 2012
  • -
  • Visiongain
  • -
  • 149 pages

Report Details

Your guide to trends and sales potential for generics

Where's the generic drugs market heading? Visiongain's updated report gives you revenue predictions to 2023. There you find data, trends, opportunities and commercial prospects.

That new study lets you assess forecasted sales at overall world market and national level. You discover the potential of the generics market, seeing how, why and where it can grow. As pharma patents expire, much opportunity remains.

Forecasts and other analyses to help you find growth potentials

In our report you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (inc. SWOT), progress, competition, developments and business outlooks. You receive 48 tables, 36 charts and six research interviews.

Our work lets you investigate the most lucrative areas of the generics industry. See the outlook for that large, expanding pharmaceutical segment. Spending restraints will benefit it.

You can stay ahead in knowledge, benefiting your research and analyses. The following sections show what you discover in our study.

Leading national markets - where will high growth occur?

In addition to analyses of the overall world market, you discover individual revenue forecasts for seven developed national markets, with sales data from 2011 to 2023.
• US
• Japan
• Germany, France, UK, Italy and Spain (EU5).

Also our work shows you individual forecasts to 2023 for seven developing countries:
• Brazil, Russian Federation, India and China (BRIC nations)
• Turkey, South Korea and Mexico.

There will be growth in established pharma markets and in developing countries. Our analyses show that Japan, India, Mexico and Brazil, in particular, will achieve high revenue growth to 2016. You see what's likely to happen. Events will influence that market.

What issues will affect the generics industry?

Our study discusses matters affecting that sector from 2012 onwards:
• US, European and Japanese regulations
• Authorised, branded and other generics, including modified products
• Patent expiries and business strategies, including patenting challenges
• Generic drug prescribing linked to budgetary constraints
• Growing consumer acceptance of generic medicines
• M&A activities, including entry of big pharma companies.

Also you find coverage of these aspects:
• European pricing systems and generic penetration
• Price changes, trends, prescribers and pharmacies
• Patient co-payment
• ANDAs and approvals
• Pathways to the market for biosimilars
• Product differentiation.

See what the future holds. You find discussions of commercial, technological, regulatory and economic issues, with emphasis on the competitive landscape and sales predictions.

Leading companies and market value in 2013

Overall world revenue for generic medicines will reach $127.8bn in 2013, our report forecasts. Rising demand for prescription drugs, expanding healthcare coverage, payers favouring generics and changes to prescribing will increase sales to 2023.

Also, our investigation discusses these specialty companies and others:
• Teva Pharmaceutical Industries
• Sandoz (Novartis)
• Mylan
• Apotex
• Hospira
• Watson Pharmaceuticals.

From this decade onwards, many opportunities will arise for generics specialists and other pharma companies producing those medicines. You see how revenues can increase.

Nine ways Generic Drugs: World Market 2013-2023 benefits you

To sum up, our report gives you the following knowledge on the topic:
• Predicted revenues to 2023 for the overall world generics market - find the industry's prospects
• Forecasting to 2023 for 14 countries in North America, Europe, Asia andLatin America - see n

Table Of Contents

Table of Contents

1. Executive Summary
1.1 Generic Drugs: Industry and Market Review
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods

2. Introduction to the World Generics Market
2.1 Generic Drugs (Generics)
2.1.1 Authorised, Branded and True Generics
2.2 The 'Evergreening' of Pharmaceuticals
2.3 Restraints Facing the World Pharmaceutical Market
2.4 Branded Pharmaceuticals: End of a Business Model?
2.5 US Regulations
2.5.1 Obtaining FDA Approval: NDAs and ANDAs
2.5.2 The Hatch-Waxman Act Title 1: Promotion of Generic Drugs
2.5.3 The Hatch-Waxman Act Title 2: Incentives for the Branded Industry
2.5.4 Consequences of the Hatch-Waxman Act
2.5.5 Me First: Timing as a Crucial Factor
2.6 European Regulations
2.6.1 Generics' Entry into the European Markets
2.6.2 Further Protection of Branded Products in the European Market
2.6.3 Variations among European Countries
2.6.4 Moving Towards Standardisation
2.6.5 The 8+2+1 Rule
2.7 Japanese Regulations
2.8 Compulsory Licensing
2.9 Generic Drugs: Overview

3. The World Generic Drugs Market, 2013-2023
3.1 The World Generic Pharmaceuticals Market in 2011
3.2 Generic Products to Benefit from Patent Expiries
3.2.1 Sales Forecast for the World Generic Drugs Market, 2012-2016
3.2.2 Sales Forecast for the World Generic Drugs Market, 2017-2023
3.3 Global Market Breakdown, 2013-2023

4. Leading Companies in the World Generics Market
4.1 Teva Pharmaceutical Industries - Prospects from 2013
4.1.1 ANDAs and Approvals
4.1.2 MandA Activity
4.2 Sandoz (Novartis) - Prospects from 2013
4.3 Mylan - Prospects from 2013
4.3.1 Mylan's Acquisition of Bioniche Pharma Holdings
4.3.2 Mylan's Acquires Exclusive Worldwide Rights to GSK's Advair, Diskus and Seretide
4.4 Apotex - Prospects from 2013
4.5 Hospira - Prospects from 2013
4.5.1 Acquisition of Orchid's Generic Injectable Pharmaceutical Business
4.5.2 Hospira's Acquisition of Javelin Pharma
4.6 Watson Pharmaceuticals - Prospects from 2013
4.6.1 ANDAs and Approvals
4.6.2 MandA Activity
4.6.3 Eden Becomes Wholly-Owned Subsidiary of Watson
4.6.4 Watson Acquires Specifar Pharmaceuticals
4.6.5 Purchase of Ascent Pharmahealth Gives Watson Strong Footprint inSoutheast Asia

5. The US Generics Market, 2013-2023
5.1 Analysis of the Current Market
5.2 The US Generics Market: Revenue Forecast 2013-2023
5.3 Regulatory Reform Can Keep the Market Growing
5.3.1 A New Pathway to the US Market for Biosimilars?
5.3.2 Reverse Payments
5.3.3 The ANDA Backlog
5.4 Growing Consumer Acceptance of Generic Medicines
5.5 Leading Companies in the US Generics Market
5.6 Concluding Remarks

6. Leading European Generics Markets, 2013-2023
6.1 Analysis of the Current Generics Market in Europe
6.2 Revenue Prospects for European Generics Markets 2013-2023
6.2.1 The Two Categories of European Market
6.2.2 European Pricing Systems and their Effect on Generic Penetration
6.2.3 Patient Co-Payment
6.2.4 Challenges with the European Regulatory Environment
6.3 The German Generics Market
6.3.1 German Generics Market: Sales Forecast 2013-2023
6.3.2 The Future of the German Generics Market
6.4 The French Generics Market
6.4.1 French Generics Market: Sales Forecast 2013-2023
6.4.2 The Future of the French Generics Market
6.5 The UK Generics Market
6.5.1 UK Generics Market: Sales Forecast 2013-2023
6.5.2 Generics Prescribing Linked to Increasing Budgetary Constraints
6.5.3 Reducing Generic Drug Prices: the Drug Tariff System
6.5.4 The Increasing Role of Pharmacists
6.5.5 Easy Entry, Strong Price Competition
6.5.6 The Future of the UK Generics Market
6.6 The Italian Generics Market
6.6.1 Italian Generics Market: Sales Forecast 2013-2023
6.6.2 Promoting Generic Penetration

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Analyzing the Global Generics Industry 2014

Analyzing the Global Generics Industry 2014

  • $ 1 750
  • Industry report
  • August 2014
  • by Aruvian's R'search

In recent times there has been a growing focus on the generic drugs industry worldwide. The patent expiry of leading drugs in recent years and also the upcoming patent expiries has put a focus on the global ...

Detailed I/E report of Fipronil export analysis

Detailed I/E report of Fipronil export analysis

  • $ 5 400
  • Industry report
  • July 2014
  • by CCM International Limited

Fipronil export analysis will help clients understandthe export situation of technical and formulations with exclusive research methods and offer not only the products'export volume, price, time, source ...

Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonists -Pipeline Insights, 2014

Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonists -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonists-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action ...

Global Markets For Generic Drugs

January 2014 $ 6 650

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.